Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.53 |
| ▸ | LOX | P28300 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10720356 | 0.79 | LOXL2 (0.49) | LOXL2LOXKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13568529 | 0.78 | ALDH1A1 (0.48) | KDM4ETTRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4906689 | 0.77 | MAOA (0.58) | SMN1; SMN2MAPTMAOAMAOBNPC1 | |
| SCHEMBL2349067 | 0.77 | TLR4 (0.64) | KDM4EALDH1A1SMN1; SMN2LMNAMAOA | |
| SCHEMBL28165557 | 0.76 | ALDH1A1 (0.38) | KDM4ETTRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29577033 | 0.74 | MAPT (0.49) | LOXL2LOXKDM4ETTRALDH1A1 | |
| SCHEMBL443116 | 0.74 | MAPT (0.49) | LOXL2LOXKDM4ETTRALDH1A1 | |
| SCHEMBL510519 | 0.74 | ALDH1A1 (0.71) | KDM4ETTRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL31556429 | 0.74 | ALDH1A1 (0.71) | KDM4ETTRALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL31238491 | 0.74 | ALDH1A1 (0.66) | KDM4EALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4051386-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114650868-A | Small molecule degradation agent of HELIOS and use method thereof | 达纳-法伯癌症研究公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| CN-113543852-A | Pyrrolopyrazole derivatives | 第一三共株式会社 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021087093-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| CN-107011250-B | Synthetic method and application of 2- (2, 6-dichlorophenoxy) pyridine compound | 温州医科大学 | 2020-08-11 | — | — | CN | disclosed |
| EP-2098517-B1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | MSD KK (JP) | 2013-12-18 | — | — | EP | disclosed |
| US-8367708-B2 | Phenyl-isoxazol-3-ol derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2098517-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | IKZF2, IKZF1, HELZ | LOXL2 2307/4885LOX 3115/4885KDM4E 825/4885 |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | GPR119, FFAR3, FFAR2 | LOXL2 426/4885LOX 1540/4885KDM4E 2580/4885 |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | LOXL2 3241/4885LOX 3677/4885KDM4E 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.